Cogstate Limited
ASX: CGS
Record revenue and margins with high‑margin software mix, but overbought RSI suggests near‑term pullback despite long‑term strength.
(Source: TradingView) 3-Month Performance Profile of CGS on a DTF compared to S&P/ASX 200 (XJO).
Cogstate posted record FY25 results with revenue of $81.98 million, up 23.7% YoY, supported by a 53% increase in clinical trial sa
🔒
Subscribers only
Sign in with your subscriber account or subscribe to access this research report.
Required subscription
Daily Digest
A$200.00
Already a subscriber?
Sign in to read this report.
Required subscription
Daily Digest
Stay informed with expert daily ASX research covering four carefully selected stocks, complete with market insights, risk ratings, and clear Buy, Hold, or Sell general guidance—delivered before the market opens each trading day.
- ✓ Four Expert-Selected ASX Stocks Daily
- ✓ Weekday Pre-Market Delivery
- ✓ In-Depth Research & Analysis
- ✓ Access to All Previous Reports
A$200.00/ 12 months
Risk:Medium
Subscribe Now →
